457 related articles for article (PubMed ID: 11308253)
41. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
[TBL] [Abstract][Full Text] [Related]
42. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
Tomita Y; Imai K; Senju S; Irie A; Inoue M; Hayashida Y; Shiraishi K; Mori T; Daigo Y; Tsunoda T; Ito T; Nomori H; Nakamura Y; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Apr; 102(4):697-705. PubMed ID: 21231984
[TBL] [Abstract][Full Text] [Related]
43. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells.
Lacabanne V; Viguier M; Guillet JG; Choppin J
Eur J Immunol; 1996 Nov; 26(11):2635-9. PubMed ID: 8921949
[TBL] [Abstract][Full Text] [Related]
44. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
45. Mapping of HLA epitopes recognized by H-2-restricted cytotoxic T lymphocytes specific for HLA using recombinant genes and synthetic peptides.
Pala P; Corradin G; Strachan T; Sodoyer R; Jordan BR; Cerottini JC; Maryanski JL
J Immunol; 1988 Feb; 140(3):871-7. PubMed ID: 2448379
[TBL] [Abstract][Full Text] [Related]
46. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
47. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
48. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H
Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861
[TBL] [Abstract][Full Text] [Related]
49. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
Fauquembergue E; Toutirais O; Tougeron D; Drouet A; Le Gallo M; Desille M; Cabillic F; de La Pintière CT; Iero M; Rivoltini L; Baert-Desurmont S; Leprince J; Vaudry H; Sesboué R; Frébourg T; Latouche JB; Catros V
J Immunother; 2010 May; 33(4):402-13. PubMed ID: 20386466
[TBL] [Abstract][Full Text] [Related]
50. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte.
Nukaya I; Yasumoto M; Iwasaki T; Ideno M; Sette A; Celis E; Takesako K; Kato I
Int J Cancer; 1999 Jan; 80(1):92-7. PubMed ID: 9935237
[TBL] [Abstract][Full Text] [Related]
51. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1.
Ikeda-Moore Y; Tomiyama H; Miwa K; Oka S; Iwamoto A; Kaneko Y; Takiguchi M
J Immunol; 1997 Dec; 159(12):6242-52. PubMed ID: 9550428
[TBL] [Abstract][Full Text] [Related]
52. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.
Torikai H; Akatsuka Y; Miyauchi H; Terakura S; Onizuka M; Tsujimura K; Miyamura K; Morishima Y; Kodera Y; Kuzushima K; Takahashi T
Bone Marrow Transplant; 2007 Jul; 40(2):165-74. PubMed ID: 17530010
[TBL] [Abstract][Full Text] [Related]
53. Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line.
Ware CF; Krangel MS; Pious D; Burakoff SJ; Strominger JL
J Immunol; 1983 Sep; 131(3):1312-7. PubMed ID: 6193184
[TBL] [Abstract][Full Text] [Related]
54. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
[TBL] [Abstract][Full Text] [Related]
55. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
[TBL] [Abstract][Full Text] [Related]
56. Identification of HLA-A24-binding peptides of Mycobacterium tuberculosis derived proteins with beta 2m linked HLA-A24 single chain expressing cells.
Ding J; Wang Y; Cheng T; Chen X; Gao B
Immunol Invest; 2010 Jan; 39(2):103-13. PubMed ID: 20136618
[TBL] [Abstract][Full Text] [Related]
57. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
58. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
[TBL] [Abstract][Full Text] [Related]
59. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes.
Doan T; Chambers M; Street M; Fernando GJ; Herd K; Lambert P; Tindle R
Virology; 1998 May; 244(2):352-64. PubMed ID: 9601506
[TBL] [Abstract][Full Text] [Related]
60. Alloreactivity as a source of high avidity peptide-specific human CTL.
Münz C; Obst R; Osen W; Stevanović S; Rammensee HG
J Immunol; 1999 Jan; 162(1):25-34. PubMed ID: 9886366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]